Strategies to Accelerate the Path to Clinic for Next-Generation Antibodies

Date: Wednesday, December 1, 2021
Time: 2 p.m. CET / 8 a.m. EST

Some of the latest promising biopharmaceutical developments rely on antibody and antibody fragments that could be engineered for a variety of clinical applications. However, these next-generation antibodies, particularly antibody fragments, possess an increased level of complexity and technical challenges that may result in longer CMC development timelines and delay to clinical trials as well as commercial launch. 

In this webinar, experts will discuss formulation development and purification strategies to increase throughput, reduce operating costs and potentially decrease development times for monoclonal antibody fragments. 

Co-organized by Catalent with HollandBIO. 

FEATURED SPEAKERS

Formulation Development Strategies of Next-Generation Antibodies
Paresh Vadgama, Principal Scientist, Biologics Formulation and Drug Product Development, Catalent 

•  Key considerations in formulation development strategy and their corresponding development challenges 
• Developing a robust aseptic fill-finish process of liquid drug products 
• Drug delivery aspects for patient-friendly dosage forms 

Maximize the Productivity of Antibody Fragment Purification and Analysis
Jonas Wege, Application Specialist, Separations & Purification, Tosoh Bioscience

•  Overview of current antibody fragment landscape and its downstream challenges 
• How transferring from a conventional batch mode to continuous processing can improve the productivity of the antibody fragment capturing process 
• Analysis of the purified antibody fragment by SEC and SEC-MALS